A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of Lapaquistat and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia

NCT00286481 Phase 3 COMPLETED

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	1362
Start date	2006-03
Completion	2007-05

Conditions

• Hypercholesterolemia

Interventions

• Lapaquistat acetate and simvastatin
• Lapaquistat acetate and simvastatin
• Simvastatin

Primary outcomes

• Change from Baseline in Low Density Lipoprotein cholesterol — Week 12 or Final Visit

Countries

United States, Canada